Alendronate Sodium Tablet
Product Images NDC 50090-5474

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-5474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

A line graph showing the cumulative incidence of hip fractures over 36 months in patients with radiographic vertebral fractures at baseline. The graph compares placebo and Alendronate Sodium, indicating lower cumulative hip fracture incidence with Alendronate Sodium versus placebo over time.*

FDA Label Image

Figure 2 (Alendronate Fig2)

A bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing the increase in bone mineral density (BMD) at three years for Alendronate 10 mg/day. It compares mean percentage BMD increase relative to placebo ± SE for U.S. and multinational studies at lumbar spine, femoral neck, and trochanter sites.*

FDA Label Image

Figure 3 (Alendronate Fig3)

This figure contains two line graphs showing the percent change from baseline in lumbar spine bone mineral density (BMD) over 36 months. It compares Alendronate 10 mg daily versus placebo in postmenopausal women. The left graph represents a U.S. study and the right graph a multinational study. Data points indicate mean percent change with standard error bars.*

FDA Label Image

Figure 4 (Alendronate Fig4)

Two bar charts displaying bone mineral density (BMD) changes from baseline in postmenopausal women over 2-year and 3-year osteoporosis prevention studies. Both charts compare BMD percentage changes at lumbar spine, femoral neck, trochanter, and total body for Alendronate 5 mg/day versus placebo groups.*

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)

Bar chart illustrating the increase in bone mineral density (BMD) at the lumbar spine, femoral neck, and trochanter after one year of Alendronate 5 mg/day treatment in glucocorticoid-treated patients. It compares mean percentage BMD increase plus standard error between U.S. and multinational study groups.*

FDA Label Image

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)

A line graph titled 'Studies in Paget's Disease of Bone' showing the effect on serum alkaline phosphatase of Alendronate 40 mg/day compared with placebo and Etidronate 400 mg/day over a 6-month period. The y-axis represents mean percent change from baseline in serum alkaline phosphatase, and the x-axis shows time in months. Data points for placebo, Etidronate, and two studies of Alendronate are plotted, illustrating changes in serum alkaline phosphatase levels over time for each treatment group.*

FDA Label Image

Chemical Structure (Alendronate Str)

Chemical structure of Alendronate Sodium, showing its molecular components including amine groups, carbon chain, phosphonate groups, sodium ion, and associated water molecules (hydrated form).*

FDA Label Image

Label Image (Lbl500905474)

Alendronate Sodium 35 mg oral tablets packaging label from A-S Medication Solutions. The label includes NDC 50090-5474-0, lot number space, and dosage instructions indicating a once weekly 35 mg dose. Storage instructions specify keeping tablets between 68 to 77 degrees Fahrenheit, with a package count of 4 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.